NDL 0.00% 3.8¢ neurodiscovery limited

research , page-9

  1. 447 Posts.
    lightbulb Created with Sketch. 1
    The drug didnt fail as a Phase I trial it passed both Phase I and Phase II but failed at Phase III and this was for another indication not neuropathic pain - also I think their partner Sosei might have a little bit of an idea of what they are doing aswell

    These people are world leaders in the field - have you seen the client base
 
watchlist Created with Sketch. Add NDL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.